<DOC>
	<DOCNO>NCT01741428</DOCNO>
	<brief_summary>Early intervention promote physical activity , dietary lifestyle change optimal medication cardiovascular risk factor reduction 3 year follow-up . A randomized Clinical Trial .</brief_summary>
	<brief_title>`` Hjerteloeftet '' ( `` HeartLift '' ) . Interaction For Preventing Cardiovascular Disease</brief_title>
	<detailed_description>Background It establish major risk factor coronary artery disease modifiable risk factor . The international Case control study across 52 country identify 90 % risk acute myocardial infarction male 94 % female modifiable risk factor smoke habit , presence hypertension , diabetes mellitus , abdominal obesity , psychological social stress hyperlipidemia ( 1 ) . It well establish intervention promote physical activity dietary change could beneficial effect reduction incidence coronary heart disease ( CHD ) ( 2 ) . Aim Study The research hypothesis person medium high risk CHD early intervention use lifestyle drug period three year reduce patient risk develop CHD estimate risk score establish risk factor CHD secondary surrogate end point . Major End Point For major end point change NORRISK Score ( 3 ) systematic review literature estimate sample size power estimate do association pilot study estimate variability score . The outcome variable difference risk score baseline three year follow-up . Considering analysis pilot study , investigator estimate variability score difference ( delta ) NORRISK standard deviation = 6.18 % . As median age sample 51 year consider change probability ten year cardiovascular death 1.5 % clinically interesting . For power 90 % type-I error 5 % study need two time 358 patient . Accepting 10 % dropout actual population , correct sample size two time 394 . A total 800 patient , two time 400 , could enough pinpoint substantial risk change baseline three year follow-up NORRISK score . Secondary end point The investigator do extensive research literature far effect lifestyle intervention different surrogate end point change Systolic Blood Pressure ( SBP ) Diastolic Blood Pressure ( DBP ) , weight kg , change waist circumference cm change TG , HDL- , LDL- Cholesterol , HBA1C . ( 4 , 5 , 6 ) . From literature estimate change baseline one year intervention : 1 . Change weight intervention - 4.2kg ( SD=5.1 ) percent - 4.75 % ( SD=5.4 ) . For control group - 0.8 kg ( SD=3.7 ) - 0.9 % ( SD=4.2 ) . 2 . Change waist circumference cm intervention - 4.4 cm ( SD=5.2 ) control - 1.3 cm ( SD=4.8 ) . 3 . Change serum lipid mg/dl : Cholesterol mg/dl intervention - 5mg/dl ( SD=2.8 ) control - 1.3 mg/dl ( SD=2.8 ) HDL mg/dl intervention 2 mg/dl ( SD=7 ) control 1 mg/dl ( SD=6 ) TG mg/dl intervention -18 mg/dl ( SD=51 ) intervention -1 mg/dl ( SD=60 ) ) Change BMI percent one year intervention group -6.7 % control -1.4 % accord ( 6 ) ) Considering figure literature power 80 % type - I error 5 % investigator need follow minimum sample size : - Change weight kg 2*27 = 54 patient , percent 2*48 = 96 patient - Change SBP DBP mmHg : SBP mmg 2*207 = 414 patient DBP mmg 2*318 = 636 patient - Change BMI percent 2*214 = 428 patient - Changes Triglycerides ( TG ) 2*169 = 338 patient In clinical trial surely enough power sample size ' 2*220 = 440 patient major surrogate outcome except change Cholesterol HDL . As intervention time longer three year instead one year , power estimate could estimate `` de facto '' power end three year observation time . Study population Selection criterion All person select general practitioner physician ( GP ) office Norway . This study use NORRISK Score ( 3 ) , new guideline prevention CardioVascular Disease ( CVD ) include calculation total risk . This new risk model base updated Norwegian data , European SCORE function , overestimate risk fatal CVD Norway . NORRISK 10-year CVD mortality present . It include gender , age , smoking level systolic blood pressure serum total Cholesterol . Ten - year risk estimate calculate NORRISK fall SCORE high- low risk estimate increase strongly age . Very persons 50 year age 10 - year risk 5 % ( European limit high risk ) . More half men age 60 year estimate risk limit , 7 % 60-year-old woman exceed limit . Even risk limit reduce 1 % young age group , woman 50 year age risk limit . NORRISK adapt current situation Norway SCORE model may useful relevant tool Norwegian clinical practice . Randomization procedure Patients randomize intervention usual care . Randomization permute block randomization utilization conceal opaque envelope . Patient information At randomization patient receive verbal write information study . This information repeat verbally . The patient sign formula `` Consent participate '' . Ethics Committee The committee may look database study ass data quality evaluate quality end point . If necessary inclusion period follow time could prolong . Recording data All case report form ( CRF ) keep analysis Feiring Heart Clinic introduction database electronically . Evaluation data All CRF 's check centrally validity completeness . Disclosure data publication All information obtain result study regard confidential appropriate analysis review perform . The result publish presented internationally . As far authorship contribution , investigator follow recommendation International Committee Medical Journal Editor ( ICMJE ) ( www.ICMJE.org ) . After publication initial report , participate investigator may prepare publish sub analysis . All sub study must approve steer committee . All participant investigator acknowledge name main publication.The recommendation STROBE group follow way ( 7 ) . Insurance All patient participate study insure accordance official Norwegian insurance regulation . End point adverse event review committee - Per Mølstad , MD , Philosophiae doctor ( PhD ) , Department cardiology , Feiring Heart Clinic - Dag Elle Rivrud , MD , Feiring Heart Clinic Start end study Start study November 25 . 2012 continue throughout 2021 . Administrative matter A. Principal/Chief investigator - Hilde Bergum , MD , Feiring Heart Clinic B . Steering Committee - Siri Skumlien , Project Director Feiring Heart Clinic - Nils Erling Myhr , Head Rehabilitation dep. , Feiring Heart Clinic - Jostein Grimsmo , MD , PhD , Chief med doctor Rehab.dep , Feiring Heart Clinic C. Reference Committee - Dag Aanensen , Participant representative - Tor Ole Klemsdal , MD , PhD , Leader section preventive cardiology . Center preventive medicine , Oslo University Hospital , Ullevål . - Sigmund Alfred Andersen , Ph.D , Professor , Norwegian School Sport Sciences - Per Mølstad , MD , PhD , Department cardiology , Feiring Heart Clinic - Joanna Kafel , M.D. , Skjetten legesenter , Nordens vei 15 2013 Skjetten - Anne Marie Aas , PhD , Researcher , Clinical nutritionist Oslo University Hospital , Aker D. Advisor ( ) /Consultant ( ) research statistical methodology - Irene Sandven , MPH , Ph.D , Researcher , Oslo Center biostatistics epidemiology , Oslo University Hospital , Ullevål .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<criteria>All male female age 35 67 middle high 10 year risk estimate include . &gt; = 0.5 % person age 50 year &gt; = 2.5 % person 5059 year &gt; = 5 % person &gt; 60 year Previous cardiovascular disease ( CHD ; peripherical atherosclerosis , deep venous thrombosis /pulmonary embolism , congenital heart disease , presence valvular heart disease ) . Lung disease restrict usual physical activity . Serious psychological problem ( hinders participation study ) All kind disease restrict perform adequate physical activity . Presence cancer shorten drastically survival .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>67 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>CVD Risk score</keyword>
	<keyword>Physical activity</keyword>
	<keyword>Overweight</keyword>
	<keyword>Cholesterol</keyword>
	<keyword>LDL-Cholesterol</keyword>
	<keyword>HDL-Cholesterol</keyword>
	<keyword>Triglycerides</keyword>
	<keyword>HbA1C</keyword>
	<keyword>Quality life</keyword>
</DOC>